ZMapp FDA Approval Status
FDA Approved: No
Brand name: ZMapp
Company: Mapp Biopharmaceutical, Inc.
Treatment for: Ebola Virus Disease
ZMapp is a combination of three chimeric monoclonal antibodies manufactured in the Nicotiana benthamiana tobacco plant. It has been used in the experimental treatment of Ebola virus disease.
Development timeline for ZMapp
|Sep 17, 2015||Experimental Ebola Treatment ZMapp is Granted Fast Track Status by the FDA|
|Feb 27, 2015||LeafBio Announces Acceptance of Investigational New Drug (IND) Application for Ebola Therapy ZMapp|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.